Graybill Bartz & Assoc Ltd. Increases Stake in Horizon Pharma PLC (HZNP)

Marco Green
May 20, 2017

The stock of Horizon Pharma PLC (NASDAQ:HZNP) is a huge mover today! The stock Fell -46.65 percent over the past six months. Horizon Pharma Plc (Call) now has $1.73 billion valuation.

While there are a number of profitability ratios that measure a company's ability to generate profit from the sales or services it provides, one of the most important is the net profit margin. Janus Capital Management LLC now owns 4,409,717 shares of the biopharmaceutical company's stock valued at $65,173,000 after buying an additional 717,643 shares during the last quarter.

They hope that the stock price will fall or that the company will fail and go bankrupt, leading the equity holders to ruin. MA bought a new stake in Horizon Pharma PLC during the first quarter worth about $151,000.

Most investors are likely looking for that next stock that is ready to take off running. BlackRock Institutional Trust Company N.A. now owns 4,057,096 shares of the biopharmaceutical company's stock valued at $73,555,000 after buying an additional 383,892 shares during the last quarter. The stock had previously closed at $15.58. Finally, Fort Point Capital Partners LLC raised its stake in shares of Horizon Pharma PLC by 59.3% in the first quarter. First Mercantile Trust Co. now owns 11,770 shares of the biopharmaceutical company's stock worth $174,000 after buying an additional 310 shares during the period.

Shares of Horizon Pharma PLC (NASDAQ:HZNP) traded up 0.74% during trading on Tuesday, hitting $10.83.

The number of shares traded in the last trading session was 6.66 Million. Highbridge Capital Management LLC now owns 1,545,169 shares of the biopharmaceutical company's stock valued at $22,837,000 after buying an additional 867,927 shares during the last quarter. Horizon Pharma, Inc. has a 52-week low of 9.45 and a 52-week high of 23.44. Harbor Advisors LLC purchased a new stake in shares of Horizon Pharma PLC during the first quarter valued at $222,000. The biopharmaceutical company reported $0.21 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.25 by $0.04. The Return on Equity (ROE) value stands at -16.4%. The business had revenue of $220.90 million during the quarter, compared to analysts' expectations of $248.71 million. During the same quarter in the prior year, the firm posted $0.34 earnings per share. The Company has 20.04 million shares outstanding while EPS in next five years is expected to reach 12.70% while EPS growth in past 5 year was 3.00%. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & worldwide trademark & copyright laws.

ILLEGAL ACTIVITY WARNING: "Short Interest in Horizon Pharma PLC (HZNP) Decreases By 7.5%" was published by The Cerbat Gem and is the property of of The Cerbat Gem.

Several analysts recently commented on HZNP shares.

Horizon Pharma, Inc. had its "outperform" rating reiterated by analysts at BMO Capital Markets. The stock presently has an average rating of "Buy" and an average price target of $21.38. Guggenheim initiated coverage on Horizon Pharma PLC in a research note on Monday, February 27th. A beta of 1 indicates that the stock price moves with the market. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned "Buy" rating by Citigroup on Monday, November 28.

Among 22 analysts covering Proctor & Gamble (NYSE:PG), 10 have Buy rating, 1 Sell and 11 Hold. The shares were sold at an average price of $16.03, for a total value of $509,882.24. GREY MICHAEL G bought 10,000 shares worth $94,800. The disclosure for this sale can be found here. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER